ClinicalTrials.gg
RecruitingNCT07001449Updated Oct 22, 2026

Effectiveness of Communication-Focused Pain Neuroscience Education in Chronic Musculoskeletal Pain

An interventional study of Pain Neuroscience Education with Communication Training and Pain Neuroscience Education without Communication Training in Chronic Musculoskeletal Pain, sponsored by University of Thessaly. Recruiting at 1 site in Greece. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by University of Thessaly · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.
Updated Oct 22, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This randomized controlled trial aims to evaluate the effectiveness of the "Algo(S)Therapy" Pain Neuroscience Education (PNE) program in patients with chronic musculoskeletal pain. The study will assess whether the integration of communication skills training for physiotherapists enhances the outcomes of PNE. Participants will be randomly assigned to one of three groups: (1) PNE with communication-focused delivery, (2) PNE without communication emphasis, or (3) standard- usual physiotherapy care. The primary objective is to determine whether PNE combined with enhanced communication skills leads to greater improvements in pain, function, and psychosocial outcomes compared to the other interventions.

Read the detailed description

This randomized controlled trial investigates the effectiveness of the "Algo(S)Therapy" Pain Neuroscience Education (PNE) program in the management of chronic musculoskeletal pain (CMP), with a focus on the added value of physiotherapists' communication skills. The study will be conducted in accordance with the CONSORT guidelines.

Eligible participants will be men and women aged 18 to 65 years, diagnosed with chronic musculoskeletal pain in the lumbar spine, neck, shoulder, or knee for more than 3 months, reporting a pain intensity ≥3/10 on the Numeric Pain Rating Scale (NPRS), and experiencing symptoms on most days of the week. All participants must be fluent in the Greek language. Exclusion criteria include acute pain, neurological or neuromuscular disorders, malignancy, recent surgeries or fractures within the past year, fibromyalgia, pregnancy, corticosteroid use, cognitive impairments that affect communication or questionnaire completion, or participation in other therapeutic programs during the study period.

Participants will be randomized into one of three groups:

Experimental Group 1: Participants will receive individualized PNE-based physiotherapy delivered by physiotherapists who have completed the full "Algo(S)Therapy" program, which includes both pain neuroscience and communication skills training specific to managing patients with chronic pain.

Experimental Group 2: Participants will receive the same PNE-based physiotherapy intervention, but from physiotherapists who have completed only the pain neuroscience component of the "Algo(S)Therapy" program. These therapists will not have received any training in communication skills or related modules.

Control Group will receive standard physiotherapy treatment without any exposure to PNE or communication-focused training.

All therapists in the experimental groups will have at least two year of experience treating patients with chronic musculoskeletal pain and will be selected based on performance in the "Algo(S)Therapy" training program. The intervention for all groups will last five weeks, with two sessions per week (total of 10 sessions).

The study will utilize validated outcome measures to evaluate pain, function, psychosocial variables, and therapeutic alliance. These include:

Numeric Pain Rating Scale (NPRS) Pain drawings (APDs) Central Sensitization Inventory (CSI) Pain Catastrophizing Scale (PCS) Tampa Scale for Kinesiophobia (TSK) Brief Illness Perception Questionnaire (B-IPQ) Pain Self-Efficacy Questionnaire (PSEQ) Pittsburgh Sleep Quality Index (PSQI) State-Trait Anxiety Inventory (STAI) Pain Disability Index (PDI) Working Alliance Inventory - Short Revised (WAI-SR) Satisfaction of treatment (Global Rating of Change - GroC) Days with disability (Recorded in an electronic data collection notebook) Adherence to Intervention (Recorded electronically) Adverse Effects (Recorded electronically)

Assessments will be conducted at three time points: baseline (pre-intervention), post-intervention, and 3-month follow-up. Statistical analysis will include repeated measures ANOVA to evaluate within- and between-group differences over time. The required sample size of 90 participants was calculated using G*Power, accounting for an estimated 10% dropout rate.

The main goal of this study is to determine whether the inclusion of communication training in a PNE-based physiotherapy program can significantly enhance clinical outcomes in patients with chronic musculoskeletal pain, compared to PNE alone or standard care.

02

Conditions studied

  • Chronic Musculoskeletal Pain

Browse trials for

Keywords

  • Pain neuroscience education
  • Communication skills
  • Chronic musculoskeletal pain
03

In context

Musculoskeletal Pain

518 studies on the registry are indexed under Musculoskeletal Pain; 127 are open to participants now.

This study's planned enrollment of 90 is above the median of 69 across 373 interventional studies indexed under Musculoskeletal Pain.

Browse Musculoskeletal Pain studies →

Lead sponsor

University of Thessaly is the lead sponsor of 195 studies on the registry; 44 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 to 65 years
  • Diagnosis of chronic musculoskeletal pain in the lumbar spine, cervical spine, shoulder, or knee
  • Pain duration longer than 3 months
  • Pain intensity ≥3/10 on the Numeric Pain Rating Scale (NPRS)
  • Pain present most days of the week
  • Able to understand and speak the Greek language

Exclusion criteria

Exclusion Criteria:

  • Acute pain in any body region
  • Neurological disorders or myopathies
  • Chronic pain of non-musculoskeletal origin
  • Active cancer diagnosis
  • History of trauma, fractures, or surgery in the past year
  • Pregnancy
  • Diagnosis of fibromyalgia
  • Cognitive impairments affecting communication or completion of questionnaires
  • Current use of medication
  • Participation in other treatment programs or alternative therapies during the study period
  • Concurrent enrollment in another clinical trial
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    PNE + Communication Skills

    Participants in this group will receive an individualized Pain Neuroscience Education (PNE) program plus usual physiotherapy care delivered by physiotherapists who completed the full "Algo(S)Therapy" training. This training included education in the neurophysiology of pain, assessment and management of chronic musculoskeletal pain, as well as the development and application of communication skills. The communication training focused on strategies such as motivational interviewing, empathy, active listening, and patient-centered interaction specifically tailored for individuals with chronic pain. The intervention will be administered over a 5-week period, with 2 sessions per week.

    Behavioral: Pain Neuroscience Education with Communication Training

  • Experimental
    PNE without Communication Training

    Participants in this group will receive an individualized Pain Neuroscience Education (PNE) intervention plus usual physiotherapy care, delivered by physiotherapists who completed only the pain neurophysiology and clinical management components of the "Algo(S)Therapy" program. These physiotherapists did not receive any formal training in communication skills, such as motivational interviewing or empathy techniques. The intervention will be administered over a 5-week period, with 2 sessions per week.

    Behavioral: Pain Neuroscience Education without Communication Training

  • Active comparator
    Usual Physiotherapy Treatment

    Participants in this group will receive usual physiotherapy care. Physiotherapists in this group have not received any training in Pain Neuroscience Education or communication techniques related to chronic pain management. No components of the "Algo(S)Therapy" program will be applied in this group.

    Behavioral: Usual Physiotherapy Treatment

Interventions

  • BehavioralPain Neuroscience Education with Communication Training

    This intervention includes individualized physiotherapy based on a Pain Neuroscience Education (PNE) framework delivered by physiotherapists who completed the full "Algo(S)Therapy" training program. The training includes education in the neurophysiology of pain, clinical reasoning for chronic musculoskeletal pain management, and structured communication skills development (e.g., motivational interviewing, empathy, active listening). The intervention is delivered twice per week over 5 weeks (10 sessions total).

  • BehavioralPain Neuroscience Education without Communication Training

    A structured PNE program focusing on the neurophysiology and clinical management of chronic musculoskeletal pain. Delivered by physiotherapists trained only in the scientific modules of the "Algo(S)Therapy" program. Does not include communication skills training. Includes 10 sessions (2/week for 5 weeks), alongside standard physiotherapy care.

  • BehavioralUsual Physiotherapy Treatment

    Usual care based on medical referral and physiotherapy assessment. Delivered by physiotherapists who have not received training in Pain Neuroscience Education or communication techniques. No components of the "Algo(S)Therapy" program are included.

06

What researchers measure

Primary outcomes

  1. Numeric Pain Rating Scale - NPRS

    Pain intensity will be assessed using the Numeric Pain Rating Scale (NPRS), where participants rate their average pain on a scale from 0 (no pain) to 10 (worst imaginable pain). The measure will be used to determine the effectiveness of each intervention in reducing chronic musculoskeletal pain.

    Time frame: Baseline, Post-intervention (Week 5), and 3-Month Follow-Up

Secondary outcomes

  1. Central Sensitisation Inventory (CSI)

    The CSI assesses symptoms related to central sensitization in chronic pain conditions. The score ranges from 0 to 100, with higher scores indicating greater sensitization.

    Time frame: Baseline, Post-intervention (Week 5), and 3-Month Follow-Up

  2. Pain Catastrophizing Scale (PCS)

    The PCS evaluates negative cognitive and emotional responses to pain, including rumination, magnification, and helplessness. Scores range from 0 to 52, with higher scores indicating greater levels of pain catastrophizing. This measure helps assess the psychological effect of the intervention.

    Time frame: Baseline, Post-intervention (Week 5), and 3-Month Follow-Up

  3. Tampa Scale for Kinesiophobia (TSK)

    The TSK measures fear of movement or re-injury, which can limit function in individuals with chronic pain. Scores range from 17 to 68, with higher scores reflecting greater kinesiophobia. This outcome examines whether the intervention improves patients' movement confidence.

    Time frame: Baseline, Post-intervention (Week 5), and 3-Month Follow-Up

  4. Pain Sensitivity Questionnaire (PSQ)

    The PSQ assesses self-reported pain sensitivity through imagined everyday painful situations. It helps identify individuals with increased pain perception, a factor often present in chronic pain conditions. The total score ranges from 0 to 10, with higher scores indicating greater pain sensitivity. This outcome evaluates whether the intervention influences pain sensitivity levels.

    Time frame: Baseline, Week 5, and 3-Month Follow-Up

  5. Pain Self-Efficacy Questionnaire (PSEQ)

    The PSEQ assesses a patient's confidence in performing activities despite their pain. Scores range from 0 to 60, with higher scores indicating stronger pain self-efficacy. This outcome evaluates the empowering effect of the intervention.

    Time frame: Baseline, Week 5, and 3-Month Follow-Up

  6. Brief Illness Perception Questionnaire (B-IPQ)

    The B-IPQ measures patients' perceptions of their illness across cognitive and emotional dimensions. The total score ranges from 0 to 80, with higher scores indicating more negative or threatening views of their pain condition. This outcome assesses changes in illness perception related to the intervention.

    Time frame: Baseline, Week 5, and 3-Month Follow-Up

  7. Pittsburgh Sleep Quality Index (PSQI)

    The PSQI evaluates sleep quality over the past month. It generates a global score ranging from 0 to 21, where scores above 5 indicate poor sleep quality. This outcome assesses whether the intervention contributes to improved sleep in chronic pain patients.

    Time frame: Baseline, Week 5, and 3-Month Follow-Up

  8. State-Trait Anxiety Inventory (STAI)

    The STAI measures both current (state) and general (trait) anxiety. Each subscale yields a score from 20 to 80, with higher scores reflecting greater anxiety levels. This outcome helps evaluate the intervention's impact on anxiety associated with chronic pain.

    Time frame: Baseline, Week 5, and 3-Month Follow-Up

  9. Pain Disability Index (ODI)

    Pain-related disability will be assessed using the Pain Disability Index (PDI), a 7-item questionnaire that evaluates interference from pain in major life domains. Each item is scored from 0 (no disability) to 10 (total disability), with a total score range of 0-70. Higher scores indicate greater functional impairment.

    Time frame: Baseline, Week 5, and 3-Month Follow-Up

  10. Working Alliance Inventory - Short Revised (WAI-SR)

    The WAI-SR assesses the quality of the therapeutic alliance between the physiotherapist and the patient. Scores range from 12 to 84, with higher scores indicating a stronger working alliance. This measure is collected post-intervention to evaluate the interpersonal impact of the therapist's communication skills.

    Time frame: Week 5 (Post-intervention only)

  11. Satisfaction with Treatment (Global Rating of Change - GROC)

    Participants will rate their perceived overall change in condition using the Global Rating of Change (GROC) scale, which typically ranges from -7 ("a very great deal worse") to +7 ("a very great deal better"). This outcome assesses overall patient satisfaction and perceived treatment effectiveness.

    Time frame: Post-intervention (Week 5) and 3-Month Follow-Up

  12. Pain Medication Consumption

    Participants will report their use of pain medication throughout the intervention period. Data will be recorded electronically frequency. This outcome assesses whether the intervention reduces reliance on pharmacological pain management.

    Time frame: Weekly during the 5-week intervention and at 3-Month Follow-Up

  13. Adherence to Intervention

    Adherence will be tracked electronically by recording participant attendance to scheduled sessions. This outcome measures compliance with the intervention protocol.

    Time frame: Throughout the 5-week intervention period

  14. Adverse Effects

    Any adverse effects related to the intervention-such as increased pain, emotional distress, or any unexpected physical or psychological responses-will be reported by participants and recorded electronically. This outcome assesses the safety and tolerability of the interventions from a patient-reported perspective and supports real-time monitoring by the research team.

    Time frame: Monitored continuously throughout the 5-week intervention

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Nov 2026, 17 months after the start.

Of 226 non-industry interventional studies with no phase under Musculoskeletal Pain, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 34. This study's planned 17 months is above that.

Counting every sponsor, half of 239 studies reached it within 12 months; a quarter within 5 and three quarters within 32.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: primary completion Aug 2026 → Nov 2026 and completion Aug 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2025
First posted
Jun 3, 2025
StartActual
Jun 17, 2025
Primary completionEst.
Nov 30, 2026was Aug 2026
CompletionEst.
Dec 30, 2026was Aug 2026
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 30, 2026→Nov 30, 2026
Oct 22, 2026
Study completion
Aug 30, 2026→Dec 30, 2026
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Primary completion Aug 30, 2026→Nov 30, 2026
    Study completion Aug 30, 2026→Dec 30, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07001449
Responsible party
Konstantina Savvoulidou (PhD Candidate, University of Thessaly) — Principal investigator
First posted
Jun 3, 2025
Start date
Jun 17, 2025
Primary completion
Nov 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Oct 22, 2026

Study contacts

Konstantina Savvoulidou
Contact
ksavvoulidou@uth.gr
+30 22310 6017
Eleni Kapreli, Professor
study chair · Physiotherapy Department, University of Thessaly, Greece

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion